We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

42 hedge funds and large institutions have $789M invested in Ambrx Biopharma Inc in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

139% more capital invested

Capital invested by funds: $331M → $789M (+$458M)

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

40% more funds holding

Funds holding: 30 → 42 (+12)

24% more call options, than puts

Call options by funds: $4.87M | Put options by funds: $3.92M

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
42
Holders Change
+12
Holders Change %
+40%
% of All Funds
0.66%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
18
Increased
13
Reduced
8
Closed
6
Calls
$4.87M
Puts
$3.92M
Net Calls
+$949K
Net Calls Change
-$9.86M

Top Buyers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
+$67.7M
2
FCM
Farallon Capital Management
California
+$24M
3
PBA
Paradigm Biocapital Advisors
New York
+$20.8M
4
CAM
Cormorant Asset Management
Massachusetts
+$14M
5
Holocene Advisors
Holocene Advisors
New York
+$11.5M

Top Sellers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
-$20.5M
2
VA
VR Adviser
New York
-$10.2M
3
FI
Fosun International
China
-$2.22M
4
Simplex Trading
Simplex Trading
Illinois
-$1.43M
5
UBS Group
UBS Group
Switzerland
-$715K
Name Holding Trade Value Shares
Change 		Change in
Stake
DGM
1
Darwin Global Management
Jersey
$275M +$67.7M +5,384,063 +48%
CAM
2
Cormorant Asset Management
Massachusetts
$158M +$14M +1,116,155 +13%
D.E. Shaw & Co
3
D.E. Shaw & Co
New York
$66.1M +$1.04M +82,356 +2%
CC
4
Commodore Capital
New York
$52.3M -$20.5M -1,628,447 -34%
VA
5
VR Adviser
New York
$40.9M -$10.2M -813,617 -25%
FCM
6
Farallon Capital Management
California
$37.3M +$24M +1,908,000 +529%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$36.4M – – –
PBA
8
Paradigm Biocapital Advisors
New York
$27.2M +$20.8M +1,650,499 New
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$15.3M +$9.04M +718,690 +341%
Holocene Advisors
10
Holocene Advisors
New York
$15M +$11.5M +913,754 New
Citadel Advisors
11
Citadel Advisors
Florida
$12M +$250K +19,889 +3%
AG
12
Artal Group
Luxembourg
$11.6M – – –
ECM
13
ExodusPoint Capital Management
New York
$7.86M +$5.76M +458,061 +2,349%
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$5.76M +$4.4M +349,938 New
Millennium Management
15
Millennium Management
New York
$4.7M +$3.45M +274,727 +2,500%
GTC
16
Ghost Tree Capital
New York
$3.92M -$148K -11,775 -5%
JP Morgan Chase
17
JP Morgan Chase
New York
$2.6M +$1.98M +157,858 New
HS
18
HighVista Strategies
Massachusetts
$2.53M +$1.93M +153,431 New
MCM
19
Moore Capital Management
New York
$2.38M +$1.82M +144,400 New
First Manhattan
20
First Manhattan
New York
$2.22M +$1.7M +135,003 New
SCM
21
Silverarc Capital Management
Massachusetts
$1.65M +$1.26M +100,000 New
SSA
22
Schonfeld Strategic Advisors
New York
$1.62M +$257K +20,400 +26%
TD Asset Management
23
TD Asset Management
Ontario, Canada
$1.05M +$627K +49,828 +358%
Manulife (Manufacturers Life Insurance)
24
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$974K +$373K +29,674 +101%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$844K -$379K -30,156 -37%
1
2

AMAM Hedge Fund Activity: Q2 2023 in Review

42 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q2 2023, worth a combined $789M — up 139% from $331M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new AMAM positions and 6 closed out — a net gain of 12 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Darwin Global Management, adding an estimated $67.7M. The largest seller was Commodore Capital, cutting an estimated $20.5M.

  • 42 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q2 2023, up from 30 in Q1 2023.
  • Funds reported $789M of Ambrx Biopharma Inc stock for Q2 2023, up 139% quarter-over-quarter.
  • 18 funds opened new Ambrx Biopharma Inc positions in Q2 2023 and 6 closed out, a net change of +12 holders.
  • The largest Ambrx Biopharma Inc buyer in Q2 2023 was Darwin Global Management, an estimated $67.7M added.
  • The largest Ambrx Biopharma Inc seller in Q2 2023 was Commodore Capital, an estimated $20.5M sold.

Based on aggregated 13F filings for Q2 2023.